Found 28 matching trials
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
PHASE1This is a Phase 1 open-label, study designed to characterize the safety, to...
Location
Washington University School of Medicine
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
PHASE2This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadju...
Location
University of California, Irvine
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
PHASE2In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene exp...
Location
UPMC Hillman Cancer Center
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
PHASE2Melanoma remains a common cancer with rising incidence, and despite signifi...
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
PHASE3This clinical trial is a prospective, multicenter, open-label, randomized, ...
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
PHASE2The purpose of this study is to determine if neoadjuvant (treatment before ...
Location
Moffitt Cancer Center
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
PHASE2The goal of this clinical trial is to test neoadjuvant dual immunotherapy i...
Location
Melanoma Institute Australia
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
PHASE1A companion platform trial to test novel targeted agents based on the patie...
Location
John Hunter Children's Hospital
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
PHASE3The purpose of this study is to demonstrate that the study drug exposure le...
Status
Active Not Recruiting
Location
Local Institution - 0125
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
PHASE3This study is researching an experimental drug called fianlimab (also known...
Location
Ironwood Cancer & Research Centers